These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30587546)

  • 1. Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma.
    Cao J; Pickup S; Clendenin C; Blouw B; Choi H; Kang D; Rosen M; O'Dwyer PJ; Zhou R
    Clin Cancer Res; 2019 Apr; 25(7):2314-2322. PubMed ID: 30587546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Arterial Input Function and Pharmacokinetic Models on DCE-MRI Biomarkers for Detection of Vascular Effect Induced by Stroma-Directed Drug in an Orthotopic Mouse Model of Pancreatic Cancer.
    Cao J; Pickup S; Rosen M; Zhou R
    Mol Imaging Biol; 2023 Aug; 25(4):638-647. PubMed ID: 37166575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).
    Wong KM; Horton KJ; Coveler AL; Hingorani SR; Harris WP
    Curr Oncol Rep; 2017 Jul; 19(7):47. PubMed ID: 28589527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
    Jacobetz MA; Chan DS; Neesse A; Bapiro TE; Cook N; Frese KK; Feig C; Nakagawa T; Caldwell ME; Zecchini HI; Lolkema MP; Jiang P; Kultti A; Thompson CB; Maneval DC; Jodrell DI; Frost GI; Shepard HM; Skepper JN; Tuveson DA
    Gut; 2013 Jan; 62(1):112-20. PubMed ID: 22466618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
    Provenzano PP; Cuevas C; Chang AE; Goel VK; Von Hoff DD; Hingorani SR
    Cancer Cell; 2012 Mar; 21(3):418-29. PubMed ID: 22439937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
    Hingorani SR; Harris WP; Beck JT; Berdov BA; Wagner SA; Pshevlotsky EM; Tjulandin SA; Gladkov OA; Holcombe RF; Korn R; Raghunand N; Dychter S; Jiang P; Shepard HM; Devoe CE
    Clin Cancer Res; 2016 Jun; 22(12):2848-54. PubMed ID: 26813359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts.
    Wegner CS; Hauge A; Gaustad JV; Andersen LMK; Simonsen TG; Galappathi K; Rofstad EK
    Acta Oncol; 2017 Dec; 56(12):1754-1762. PubMed ID: 28661213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
    Gourd E
    Lancet Oncol; 2018 Feb; 19(2):e81. PubMed ID: 29276021
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of pancreatic tumor development in KPC mice using multi-parametric MRI.
    Vohra R; Park J; Wang YN; Gravelle K; Whang S; Hwang JH; Lee D
    Cancer Imaging; 2018 Nov; 18(1):41. PubMed ID: 30409175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response.
    Lim CY; Chang JH; Lee WS; Lee KM; Yoon YC; Kim J; Park IY
    Pancreatology; 2018 Dec; 18(8):913-927. PubMed ID: 30292644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeatability and correlations of dynamic contrast enhanced and T2* MRI in patients with advanced pancreatic ductal adenocarcinoma.
    Klaassen R; Gurney-Champion OJ; Wilmink JW; Besselink MG; Engelbrecht MRW; Stoker J; Nederveen AJ; van Laarhoven HWM
    Magn Reson Imaging; 2018 Jul; 50():1-9. PubMed ID: 29476781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal biology and therapy in pancreatic cancer.
    Neesse A; Michl P; Frese KK; Feig C; Cook N; Jacobetz MA; Lolkema MP; Buchholz M; Olive KP; Gress TM; Tuveson DA
    Gut; 2011 Jun; 60(6):861-8. PubMed ID: 20966025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization.
    Heid I; Trajkovic-Arsic M; Lohöfer F; Kaissis G; Harder FN; Mayer M; Topping GJ; Jungmann F; Crone B; Wildgruber M; Karst U; Liotta L; Algül H; Yen HY; Steiger K; Weichert W; Siveke JT; Makowski MR; Braren RF
    Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):115-129. PubMed ID: 36074156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of dynamic contrast-enhanced magnetic resonance imaging in the differentiation of pancreatic ductal adenocarcinoma from other pancreatic solid lesions.
    Liu K; Xie P; Peng W; Zhou Z
    J Comput Assist Tomogr; 2014; 38(5):681-6. PubMed ID: 24943251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative dynamic contrast-enhanced MR imaging for the preliminary prediction of the response to gemcitabine-based chemotherapy in advanced pancreatic ductal carcinoma.
    Tang W; Liu W; Li HM; Wang QF; Fu CX; Wang XH; Zhou LP; Peng WJ
    Eur J Radiol; 2019 Dec; 121():108734. PubMed ID: 31743881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.
    Neesse A; Frese KK; Bapiro TE; Nakagawa T; Sternlicht MD; Seeley TW; Pilarsky C; Jodrell DI; Spong SM; Tuveson DA
    Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12325-30. PubMed ID: 23836645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma.
    Hay CA; Sor R; Flowers AJ; Clendenin C; Byrne KT
    J Vis Exp; 2019 Nov; (153):. PubMed ID: 31814615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma.
    Elahi-Gedwillo KY; Carlson M; Zettervall J; Provenzano PP
    Cancer Res; 2019 Jan; 79(2):372-386. PubMed ID: 30401713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Point-of-Care Perfusion Phantom: A Pilot Study.
    Kim H; Morgan DE; Schexnailder P; Navari RM; Williams GR; Bart Rose J; Li Y; Paluri R
    Invest Radiol; 2019 Jan; 54(1):16-22. PubMed ID: 30138218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.
    Jiang H; Torphy RJ; Steiger K; Hongo H; Ritchie AJ; Kriegsmann M; Horst D; Umetsu SE; Joseph NM; McGregor K; Pishvaian MJ; Blais EM; Lu B; Li M; Hollingsworth M; Stashko C; Volmar K; Yeh JJ; Weaver VM; Wang ZJ; Tempero MA; Weichert W; Collisson EA
    J Clin Invest; 2020 Sep; 130(9):4704-4709. PubMed ID: 32749238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.